Journal article
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors
Abstract
BACKGROUND: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3b/4, single-group cohort study that evaluated andexanet alfa in patients with acute major bleeding. The results of the final analyses are presented.
METHODS: Patients with acute major bleeding …
Authors
Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM
Journal
Circulation, Vol. 147, No. 13, pp. 1026–1038
Publisher
Wolters Kluwer
Publication Date
March 28, 2023
DOI
10.1161/circulationaha.121.057844
ISSN
0009-7322